CANSINO BIOLOGICS INC.

Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange CANSINO BIOLOGICS INC. stocks are traded under the ticker CJH.

CANSINO BIOLOGICS INC. is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.

CJH earnings for the last quarter are −0.08 EUR per share, whereas the estimation was −0.03 EUR resulting in a −171.73% surprise. The estimated earnings for the next quarter are −0.18 EUR per share. See more details about CANSINO BIOLOGICS INC. earnings.

CANSINO BIOLOGICS INC. revenue for the last quarter amounts to ‪19.39 M‬ EUR despite the estimated figure of ‪15.38 M‬ EUR. In the next quarter revenue is expected to reach ‪24.33 M‬ EUR.

Yes, you can track CANSINO BIOLOGICS INC. financials in yearly and quarterly reports right on TradingView.

Like other stocks, CJH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CANSINO BIOLOGICS INC. stock right from TradingView charts — choose your broker and connect to your account.

CJH reached its all-time high on Feb 17, 2021 with the price of 46.6000 EUR, and its all-time low was 1.7985 EUR and was reached on Feb 5, 2024.
See other stocks reaching their highest and lowest prices.

As of Apr 25, 2024, the company has ‪1.49 K‬ employees. See our rating of the largest employees — is CANSINO BIOLOGICS INC. on this list?

We've gathered analysts' opinions on CANSINO BIOLOGICS INC. future price: according to them, CJH price has a max estimate of 3.30 EUR and a min estimate of 2.18 EUR. Read a more detailed CANSINO BIOLOGICS INC. forecast: see what analysts think of CANSINO BIOLOGICS INC. and suggest that you do with its stocks.

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CANSINO BIOLOGICS INC. EBITDA is ‪−234.26 M‬ EUR, and current EBITDA margin is −552.08%. See more stats in CANSINO BIOLOGICS INC. financial statements.